ABT Aqua Bio Technology

Aqua Bio Technology Asa – Result of Subsequent Offering

Aqua Bio Technology Asa – Result of Subsequent Offering

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company") on 4 December 2018 and 12 February 2019 regarding, inter alia, a private placement (the "Private Placement") and a following subsequent offering with gross proceeds of up to NOK 551,250 through issuance of new shares at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The investors in the Subsequent Offering will also receive one (1) warrant per share applied for and allocated in the Subsequent Offering.

The application period in the Subsequent Offering ended on 28 February 2019 at 16.30 CET. At the end of the application period, the Company had received applications of approximately NOK 302,240 in the Subsequent Offering through subscription of 120,896 new shares.

The Company`s board of directors (the "Board") has now allocated shares and warrants in the Subsequent Offering, which implies that the Company will issue 120,896 new shares and 120,896 new warrants related to the Subsequent Offering. Allocation letters, regarding the number of shares and warrants allocated and the subscription amount to be paid, will be distributed to the subscribers shortly.

For further information, please call Arvid Lindberg, head of Sales & Marketing, telephone or .

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT`s cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqya Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.





EN
04/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aqua Bio Technology

 PRESS RELEASE

Aqua Bio Technology ASA: Safety studies of 6 products from the product...

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approvedReference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 1...

 PRESS RELEASE

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produkts...

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent Det vises til børsmelding av vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være e...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with...

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform Restorsea's commercialization of Aqua Bio Technologies ASA's hatching fluid ingredient (Aquabeautine XL) continues. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. In connection with Hydrafacial`s merger with Vesper Healthcare and the contemplated listing on (NASDAQ), Restorsea is presented as . In Q3 20...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restors...

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter. Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs. I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på (NASDAQ), presenteres Restorsea som . Hydrafacial opplyser at selskapet per Q3 2020 har utpl...

 PRESS RELEASE

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - dis...

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - distribution agreement for New Zealand and Australia close Reference is made to where it is informed that Aqua Bio Technology ASA (ABT) is acquiring all rights to Moana Skincare . This acquisition has now been completed and in the near future ABT expects to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled na...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch